Home › NDC Lookup › RxCUI directory › RxCUI 754503

Olanzapine 10 MG Disintegrating Oral Tablet [Zyprexa] — RxCUI 754503

RxNorm drug concept · Semantic branded drug
RxCUI 754503 Semantic branded drug · SBD ● Current RxNorm concept 11 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI754503
Official nameOlanzapine 10 MG Disintegrating Oral Tablet [Zyprexa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZyprexa Zydis 10 MG Disintegrating Oral Tablet
FDA products mapped11
Package NDCs mapped11
Reported Medicaid activity (SDUD)463 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olanzapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats schizophrenia and manic or mixed episodes of bipolar I disorder, and can be added to lithium or valproate. An injection form is used for sudden agitation with those condi...
  • Oral olanzapine is usually taken once a day, with or without food. Take it as your prescriber directs and don’t stop on your own. Injections are given by a healthcare professional.
  • Sleepiness, dizziness, dry mouth, constipation, increased appetite and weight gain are common. Stand up slowly, especially at first. Your prescriber will check blood sugar, cholest...
  • Call right away for fever with stiff muscles or confusion, a severe rash, fainting, seizures, uncontrolled movements, extreme thirst or urination, or thoughts of self-harm.
📖 Read our full Olanzapine guide →

🕸️ Concept Web — How Olanzapine 10 MG Disintegrating Oral Tablet [Zyp... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Olanzapine 10 MG Disintegrating Oral Tablet [Zyprexa] RxCUI 754503

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Olanzapine 61381
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zyprexa 135423
  3. Dose forms 12

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Olanzapine Disintegrating Oral Tablet 374627
    • Olanzapine Disintegrating Oral Product 1295734
    • Olanzapine Oral Product 1159557
    • Olanzapine Pill 1159558
    • Olanzapine Disintegrating Oral Tablet [Zyprexa] 754502
    • Zyprexa Disintegrating Oral Product 1296405
    • Zyprexa Oral Product 1186672
    • Zyprexa Pill 1186673
    • +4 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Olanzapine 10 MG Disintegrating Oral Tablet SCD · 312076
  • Olanzapine 10 MG SCDC · 316404
  • Olanzapine Disintegrating Oral Tablet SCDF · 374627
  • Olanzapine Disintegrating Oral Product SCDG · 1295734
  • Olanzapine Oral Product SCDG · 1159557
  • Olanzapine Pill SCDG · 1159558

Brand-Name Concepts

  • Olanzapine 10 MG [Zyprexa] SBDC · 565155
  • Olanzapine Disintegrating Oral Tablet [Zyprexa] SBDF · 754502
  • Zyprexa Disintegrating Oral Product SBDG · 1296405
  • Zyprexa Oral Product SBDG · 1186672
  • Zyprexa Pill SBDG · 1186673
  • Zyprexa BN · 135423

📦 FDA Products & Package NDCs

11 products · 11 package NDCs
11 package NDCs map to RxCUI 754503 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61269-0630-30 30 TABLET in 1 BOTTLE (61269-630-30) Zyprexa H2-Pharma LLC 1997-06-23
61269-0631-30 30 TABLET in 1 BOTTLE (61269-631-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0632-30 30 TABLET in 1 BOTTLE (61269-632-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0633-30 30 TABLET in 1 BOTTLE (61269-633-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0634-30 30 TABLET in 1 BOTTLE (61269-634-30) Zyprexa H2-Pharma LLC 2000-01-10
61269-0635-30 30 TABLET in 1 BOTTLE (61269-635-30) Zyprexa H2-Pharma LLC 2001-03-01
61269-0640-20 1 VIAL in 1 CARTON (61269-640-20) / 2 mL in 1 VIAL ZYPREXA Intramuscular H2-Pharma LLC 2004-04-01
61269-0650-35 30 DOSE PACK in 1 CARTON (61269-650-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2000-06-01
61269-0651-35 30 DOSE PACK in 1 CARTON (61269-651-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2000-06-01
61269-0652-35 30 DOSE PACK in 1 CARTON (61269-652-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2001-09-01
61269-0653-35 30 DOSE PACK in 1 CARTON (61269-653-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2001-09-01
Observed labelers: H2-Pharma LLC (11) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.